Drug Trial Radar · NCT04411030
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
May 20, 2020
Primary completion
Aug 23, 2020
Study completion Aug 29, 2020
Sponsor
- Lead sponsor
- Astex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In Part 1, the primary objective is to investigate the effect of multiple doses of itraconazole, an inhibitor of CYP3A4, on the pharmacokinetic (PK) profile of a single dose of ASTX660. In Part 2, the primary objective is to investigate the effect of a single dose of ASTX660 on the pharmacokinetics of the CYP3A4 substrate midazolam and its metabolite, 1-hydroxy midazolam. Safety and tolerability of a single dose of ASTX660 in the absence and presence of multiple doses of the CYP3A4 inhibitor itraconazole and in the presence of a single dose of the CYP3A4 substrate midazolam will also be evaluated.
Conditions
- Healthy Volunteer
Interventions
ASTX660Drug
Form: capsule; Route of administration: oral
MidazolamDrug
Form: syrup; Route of administration: oral
ItraconazoleDrug
Form: capsule; Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameter of ASTX660: CmaxTime frame: From predose up to Day 14
- Pharmacokinetic parameter of ASTX660: AUC0-tTime frame: From predose up to Day 14
- Pharmacokinetic parameter of ASTX660: AUC0-24Time frame: From predose up to Day 14
- Pharmacokinetic parameter of ASTX660: AUC0-infTime frame: From predose up to Day 14
- Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: CmaxTime frame: From predose up to Day 9
- Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-tTime frame: From predose up to Day 9
- Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-24Time frame: From predose up to Day 9
- Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-infTime frame: From predose up to Day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS Bio-kinetic
Springfield, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.